Combination Therapy for EGFR-Mutated Lung Cancer
Mené sur 557 patients atteints d'un cancer du poumon non à petites cellules de stade avancé et présentant une mutation au niveau du gène EGFR (délétion de l'exon 19 ou mutation L858R), cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'une chimiothérapie à l'osimertinib en traitement de première ligne
Targeted therapy has improved prognoses for patients with advanced non–small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),1 and a second trial, AURA3, showed that resistance mutations could be detected and then targeted with osimertinib.2 FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 months.3,4 Osimertinib became the standard therapy for advanced NSCLC with EGFR-sensitive mutations. The story (...)